Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Garry Michael

Nurse Practitioner, Primary Care Macon, GA Nurse Practitioner

NPI 1093070096 CMS profile 10926697

3708 Northside Dr, Macon, GA 31210

Open in the dashboard

General payments

$2,085

47 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garry Michael of Macon, GA is reported in the CMS Open Payments database as having received $2,085 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $160 5
2024 General $162 4
2023 General $549 14
2022 General $631 12
2021 General $583 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garry Michael
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Garry Michael were reported at $160. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Garry Michael Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $583 $137 $39–$445 $132
2022 $631 $139 $44–$421 $149
2023 $549 $163 $53–$481 $160
2024 $162 $176 $54–$511 $164
2025 $160 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,749 37 payments
  2. Avanos Medical $114 1 payment
  3. Cumberland Pharmaceuticals, Inc. $79 3 payments
  4. Medtronic, Inc. $77 3 payments
  5. Amgen Inc. $38 2 payments
  6. Radius Health, Inc. $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,085 47 payments
Products named General payments · program years 2021–2025
  1. Superion Indirect Decompression System $950 21 payments
  2. SPECTRA WAVEWRITER Pain Management $490 7 payments
  3. WaveWriter Alpha Prime 16 $120 3 payments
  4. ON-Q* PUMP AND ACCESSORIES $114 1 payment
  5. General - Vascular Access $97 1 payment
  6. CALDOLOR $79 3 payments
  7. Spectra WaveWriter Spectra WaveWriter_NMD $74 3 payments
  8. EVENITY $38 2 payments
  9. Prolia $38 2 payments
  10. UNID_PASS $35 1 payment
  11. Other $79 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

259

Median for Nurse Practitioner: 389

Drug cost

$2,110

Median for Nurse Practitioner: $21,885

Branded share of claims

6.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 105 $782
Tizanidine Hcl Generic 80 $741
Cyclobenzaprine Hcl Generic 18 $323
Pregabalin Generic 14 $156
Acetaminophen-Codeine Acetaminophen With Codeine Brand 17 $78
Tramadol Hcl Generic 11 $18
Diazepam Generic 14 $12

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$55,429

Of which drugs: $3,604

Medicare patients

307

Average age 74

Services billed

5,141

181 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Chronic kidney disease 38%
Osteoporosis 34%
Ischemic heart disease 31%
Depression 28%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 71 3,360 $335
Injection, methylprednisolone acetate, 40 mg J1030 Office 25 25 $106

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record